Details of the Drug Pharmacogenomic Perturbation Atlas

Triclosan Drug Info

triclosan; 3380-34-5; 5-CHLORO-2-(2,4-DICHLOROPHENOXY)PHENOL; 2,4,4'-Trichloro-2'-hydroxydiphenyl ether; Irgasan; Cloxifenolum; Triclosanum; Irgasan DP300; Stri-Dex Face Wash; Phenol, 5-chloro-2-(2,4-dichlorophenoxy)-; Lexol 300; Stri-Dex Cleansing Bar; 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol; Triclosanum [INN-Latin]; CH 3565; DP-300; Caswell No 186A; C12H7Cl3O2; UNII-4NM5039Y5X; HSDB 7194; CHEBI:164200; Ether, 2'-hydroxy-2,4,4'-trichlorodiphenyl; Phenyl ether, 2'-hydroxy-2,4,4'-trichloro-; EINECS 222-182-2; CHEMBL849; EPA; Aquasept; Cliniclean; Cloxifenol; Manusept; Sapoderm; TCL; Trisan; Clearasil DailyFace Wash; Dermtek Brand of Triclosan; GlaxoSmithKline Brand of Triclosan; Microshield T; Oxy Skin Wash; Pharmachem Brand of Triclosan; Reckitt Brand of Triclosan; SSL Brand of Triclosan; Ster Zac Bath Concentrate; SterZac Bath Concentrate; Trans Canaderm Brand of Triclosan; Triclosan Pharmachem Brand; Triclosan Reckitt Brand; IN1424; Irgasan DP 300; CH-3565; Johnson & Johnson Brand of Triclosan; Procter & Gamble Brand of Triclosan; Ster-Zac Bath Concentrate; Stri-Dex cleansing bar (TN); Triclosan (USP/INN); Triclosan [USAN:BAN:INN]; 2,4,4'-Trichloro-2'-hydroxy diphenyl ether; 2-Hydroxy-2',4,4'-trichlorodiphenyl Ether; WL-1001

Therapeutic Class

Antibiotics

Cross-matching ID

PubChem CID

5564

ChEBI ID

CHEMBL164200

CAS Number

CAS 3380-34-5

TTD Drug ID

D00CSQ

General Information of Drug (ID: DMZUR4N)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Cysteine and methionine metabolism	2.19	0.00e+0	43/50 (86%)	PSAT1;GCLM;CTH;...
Glycine, serine and threonine metabolism	1.94	2.87e-3	31/40 (77.5%)	SHMT2;PSAT1;CTH;...
Porphyrin and chlorophyll metabolism	1.93	1.91e-3	23/43 (53.49%)	HMOX1;CP;HMBS;...
One carbon pool by folate	1.87	5.74e-3	15/20 (75%)	SHMT2;MTHFD2;TYMS
Pyrimidine metabolism	1.76	1.49e-2	40/56 (71.43%)	DUT;UCK2;ENPP1;...
Graft-versus-host disease	-1.61	4.92e-2	32/42 (76.19%)	HLA-DRB1;HLA-A;KLRD1;...
Asthma	-1.62	4.94e-2	25/31 (80.65%)	HLA-DRB1;IL5;EPX;...
Influenza A	-1.63	4.77e-2	156/172 (90.7%)	NXF3;PIK3R2;HLA-DRB1;...
Glycolysis / Gluconeogenesis	-1.63	4.94e-2	56/67 (83.58%)	ENO1;ADH1A;ALDH7A1;...
Axon guidance	-1.65	4.38e-2	151/182 (82.97%)	PPP3R1;RAC1;NRP1;...
Fructose and mannose metabolism	-1.65	4.16e-2	30/33 (90.91%)	TPI1;ALDOB;SORD;...
Aldosterone-regulated sodium reabsorption	-1.66	3.98e-2	34/37 (91.89%)	PIK3R1;SFN;FXYD2;...
Antigen processing and presentation	-1.66	4.15e-2	60/78 (76.92%)	HLA-DRB1;TAP1;HLA-A;...
Hippo signaling pathway	-1.66	4.28e-2	120/186 (64.52%)	CCND3;RASSF2;BMP6;...
Th1 and Th2 cell differentiation	-1.67	4.35e-2	80/92 (86.96%)	IL5;TBX21;MAF;...
Th17 cell differentiation	-1.67	4.43e-2	95/107 (88.79%)	HLA-DRB1;LCK;IL21;...
T cell receptor signaling pathway	-1.67	4.44e-2	93/104 (89.42%)	IL5;MAP2K2;IKBKB;...
Yersinia infection	-1.68	4.29e-2	120/137 (87.59%)	IRF3;ACTR2;CRK;...
Inflammatory mediator regulation of TRP channels	-1.69	4.13e-2	82/98 (83.67%)	PIK3R1;CAMK2G;ITPR2;...
Autoimmune thyroid disease	-1.70	4.13e-2	46/53 (86.79%)	HLA-DRB1;HLA-A;IL5;...
Basal cell carcinoma	-1.71	4.03e-2	41/63 (65.08%)	SMO;GLI3;BMP4;...
Tight junction	-1.71	4.32e-2	130/169 (76.92%)	CLDN7;CLDN18;ROCK1;...
Staphylococcus aureus infection	-1.72	4.11e-2	72/95 (75.79%)	PTAFR;FPR3;C3AR1;...
Human immunodeficiency virus 1 infection	-1.73	4.33e-2	189/212 (89.15%)	IKBKB;TRADD;MAP2K7;...
Chagas disease	-1.75	4.09e-2	93/102 (91.18%)	GNA11;CALR;GNAI3;...
Salmonella infection	-1.76	4.50e-2	198/249 (79.52%)	KPNA4;TLR5;MYL7;...
Allograft rejection	-1.84	1.09e-2	32/38 (84.21%)	HLA-DRB1;HLA-A;IL5;...
Type I diabetes mellitus	-1.85	1.05e-2	38/43 (88.37%)	INS;CD86;HLA-DPB1;...
Neutrophil extracellular trap formation	-1.86	1.00e-2	101/189 (53.44%)	C3;VWF;ATG7;...
Inflammatory bowel disease	-1.88	9.37e-3	58/65 (89.23%)	HLA-DRB1;IL21;IL23A;...
Retinol metabolism	-1.88	1.12e-2	41/68 (60.29%)	HSD17B6;CYP2C9;RDH16;...
Tyrosine metabolism	-1.88	1.41e-2	30/36 (83.33%)	ADH1A;ADH1C;TYR;...
PD-L1 expression and PD-1 checkpoint pathway in cancer	-1.89	1.41e-2	79/89 (88.76%)	RPS6KB1;CSNK2A1;MAPK13;...
Pentose phosphate pathway	-1.94	1.41e-2	25/30 (83.33%)	ALDOA;GPI;ALDOB;...
Steroid biosynthesis	-2.23	0.00e+0	19/20 (95%)	HSD17B7;FDFT1;CYP27B1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 3.33uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	1.25uM - 40uM	3H, 6H, 24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.04uM - 10uM	24H